Page last updated: 2024-11-05

trihexyphenidyl and Cardiovascular Diseases

trihexyphenidyl has been researched along with Cardiovascular Diseases in 2 studies

Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"Harmine is a β-carboline alkaloid that displays antidepressant, antitumor and other pharmacological effects."1.62Central inhibition prevents the in vivo acute toxicity of harmine in mice. ( Gao, S; Li, J; Li, X; Liang, H; Lv, Y; Tang, X; Wang, M; Xiao, L; Zhang, J; Zou, H, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Lv, Y1
Liang, H1
Li, J1
Li, X1
Tang, X1
Gao, S1
Zou, H1
Zhang, J1
Wang, M1
Xiao, L1
Pomara, N1
Sidtis, J1

Other Studies

2 other studies available for trihexyphenidyl and Cardiovascular Diseases

ArticleYear
Central inhibition prevents the in vivo acute toxicity of harmine in mice.
    The Journal of toxicological sciences, 2021, Volume: 46, Issue:6

    Topics: Acetylcholinesterase; Anesthetics; Animals; Cardiovascular Diseases; Central Nervous System Diseases

2021
Apolipoprotein E epsilon4 and anticholinergic cognitive toxicity.
    Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:11

    Topics: Aged; Alleles; Apolipoprotein E4; Cardiovascular Diseases; Cholinergic Antagonists; Cognition Disord

2009